Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
| Authors | Alessandro Rambaldi, Alessandra Iurlo, Alessandro M Vannucchi, Richard Noble, Nikolas von Bubnoff, Attilio Guarini, Bruno Martino, Antonio Pezzutto, Giuseppe Carli, Marianna De Muro, Stefania Luciani, Mary Frances McMullin, Nathalie Cambier, Jean-Pierre Marolleau, Ruben A Mesa, Raoul Tibes, Alessandro Pancrazzi, Francesca Gesullo, Paolo Bettica, Sara Manzoni, Silvia Di Tollo |
| Journal | Leukemia
(Leukemia)
Vol. 34
Issue 8
Pg. 2234-2237
(08 2020)
ISSN: 1476-5551 [Electronic] England |
| PMID | 32047238
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Letter, Multicenter Study, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Carbamates
- givinostat
- JAK2 protein, human
- Janus Kinase 2
|
| Topics |
- Adult
- Aged
- Aged, 80 and over
- Carbamates
(adverse effects, therapeutic use)
- Female
- Humans
- Janus Kinase 2
(genetics)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Mutation
- Polycythemia Vera
(drug therapy, genetics, psychology)
- Quality of Life
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
